Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Always Active
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Join IceCure Medical at CIRSE 2024!
The Choice of Cryoablation – IceCure at CIRSE 2024
Attending CIRSE 2024 in Lisbon? Be sure to meet IceCure at Booth 15 to learn about our advanced minimally invasive cryoablation for tumours and women's health.

We have a great line up activities including live demonstrations, an exciting "Cryo Quiz" and presentation led by Prof. Julien Frandon, and participation in the hands-on ablation sessions. See our full schedule below or click here.
IceCure Medical is committed to offering interventional radiologists the choice of cryoablation for optimal tumour destruction with our liquid nitrogen-based ProSense™ System.

ProSense System Advantages:
Effective Freeze with rapid & stable temperature drop to -160°± 10°C
Large lethal zone enables target tissue engulfment with adequate margin
Easy-to-operate single cryoprobe, liquid nitrogen-based system with no gas lines or on-site technician required
ProSense is suited to treat a wide range of clinical indications including breast, renal, lung, musculoskeletal, and more.
A New Hope for Breast Cancer: The Choice of Cryoablation
IceCure's landmark ICE3 Trial on the cryoablation of early-stage, low-risk breast cancer* has yielded promising results:
96.3% free from local recurrence in patients treated with ProSense & hormone therapy
100% doctor & patient satisfaction
100% safe procedure – no significant device-related adverse events for procedures that followed protocol guidelines
*The breast cancer indication for the ProSense® System is currently under review by the FDA and has not yet received marketing clearance in the US. ProSense™ is cleared for the treatment of breast cancer in the EU and other select markets. Clinical indications vary by region, please contact us for additional details.
Meet Prof. Frandon & Take our Cryo Quiz
Join IceCure for in-booth ProSense case presentations lead by expert user, Professor Julien Frandon of CHU de Nimes on Monday, September 16 at 11:00 AM CEST.

Think you know all there is to know about liquid nitrogen cryoablation? See if you have what it takes to participate in our Cryo Quiz and test your knowledge!
Hands-On Ablation Session
Ready to get your hands-on a ProSense? Come witness the power of liquid nitrogen cryoablation at the CIRSE hands-on cold ablation sessions lead by expert ProSense users and the IceCure team. There are three separate sessions on Tuesday, September 17. Click here to learn more about participating.

We are looking forward to seeing you in Lisbon. If you have any questions or would like to schedule a meeting, please complete our contact us form.

All the best,

Tlalit Bussi Tel Tzure
VP Business Development & Global Marketing
IceCure Medical
tlalitb@icecure-medical.com
info@icecure-medical.com
IceCure Medical, LTD
7 Ha'Eshel St, PO Box 3163, Caesarea, 3079504, Israel
© 2024 All Rights Reserved IceCure Medical